A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Concern over the side effects of anti-obesity medications, particularly if severe, has grown as their use has increased. Thus, the objective was to use trends in the reporting of suspected adverse events associated with anti-obesity medications that…
OBJECTIVE: To characterize the weight fluctuation and explore its influencing factors after glucagon-like peptide 1 receptor agonist (GLP-1RA) treatment in patients with overweight or obesity. METHODS: This retrospective cohort study enrolled 679 pat…
Tau hyper-phosphorylation has been recognized as an essential contributor to neurodegeneration in Alzheimer's disease (AD) and related tauopathies. In the last decade, tau hyper-phosphorylation has gained considerable concern in AD therapeutic develo…
INTRODUCTION: Although the onset and progression of diabetic microvascular complications are linked to glycemic control, various antihyperglycemic drugs with distinct treatment targets may positively impact microvascular lesions beyond their glucose-…
With obesity affecting over 40% of U.S. adults, bariatric surgery (BS) has become a cornerstone treatment, leading to massive weight loss (MWL) but also significant nutritional challenges. As demand for body contouring surgery (BCS) grows among post-…
Pre-pregnancy obesity (PPO) seriously threatens the health of both mother and offspring. Pre-pregnancy weight management is particularly important for the prevention of metabolic diseases in offspring. Semaglutide is one of the most effective glucago…
. Obesity as a chronic disease: the key role of new therapies. The global prevalence of overweight and obesity has risen dramatically, with obesity now recognized as a chronic, progressive, and multifactorial disease linked to major health complicati…
The aim of this study was to design a poorly water-soluble electrostatic nanocomplex of semaglutide (SMG) with protamine sulfate (PS) and zinc ions (Zn) for prolonged subcutaneous delivery. Complexation of SMG with the cationic peptide PS increased t…
INTRODUCTION: The progression of diabetes status in post-stroke patients remains under-investigated, particularly regarding new treatments for type II diabetes mellitus (DM II), like glucagon-like peptide 1 receptor agonists (GLP-1-RA) and sodium-glu…
OBJECTIVE: This study aimed to assess the effects of metformin (MET) monotherapy versus a combination of semaglutide and MET on weight, metabolism, reproductive function, and inflammatory markers in women with polycystic ovary syndrome (PCOS). METHOD…
Subcutaneous glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to reduce risk of major adverse cardiac events (MACE) for patients with type 2 diabetes (T2DM) who have or are at high risk of cardiovascular disease, but the evaluati…
Obesity is the most prevalent condition in high-income nations, primarily associated with increased risk of diabetes, cardiovascular disease (CVD), hypertension, and hyperlipidemia. Lifestyle modifications are a key determinant in non-pharmacological…
The rise of compounded weight-loss drugs has emerged as a pressing global health issue, threatening consumers and health-care systems. Factors fueling this crisis include the desire for rapid weight-loss options, inadequate regulatory frameworks, and…
RATIONALE: Glucagon-like peptide-1 (GLP-1) receptor agonists reduce alcohol consumption in rodents and non-human primates. Semaglutide is a new long-acting GLP-1 receptor agonist, widely used in the clinic against type 2 diabetes and obesity. It is a…
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality. Semaglutide 2.4 mg (Wegovy) has demonstrated improved outcomes in patients with overweight or obesity (ov/ob) and ASCVD, but its impact on medic…
BACKGROUND & AIMS: In phase 2 studies, efruxifermin, an Fc-FGF21 analog, significantly reduced steatohepatitis and fibrosis in patients with non-alcoholic steatohepatitis, now called metabolic dysfunction-associated steatohepatitis (MASH), for which…
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for type 2 diabetes and obesity, delivering robust metabolic and cardiovascular benefits. However, their potential impact on tumorigenesis remains debated. Preclinical findings in r…
Semaglutide (SGL), a long-acting GLP-1 (Glucagon-like peptide) receptor agonist, is a 31-amino acid peptide modified with a C18 fatty diacid for albumin binding. Peptides are fragile and susceptible to degradation during formulation, storage, and tra…